References

1. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007; 4: 37-45.

2. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45:1077-1097.

3. Maddox GL. The Encyclopedia of Aging. 3rd ed. New York: Springer, 1987.

4. Gorman M. Development and the rights of older people. In: Randel J, German T, Ewing D, eds. The Ageing and Development Report: Poverty, Independence and the World's Older People. London: Earthscan Publications, 1993:3-21.

5. World Health Organization (WHO). Definition of an older or elderly person. 2008. Accessed January 2008. Available at: http://www.who.int/healthinfo/survey/ageingdefiiolder/en/index.html

6. Costa PT, McCrae RR. Functional Age: A Conceptual and Empirical Critique. Washington, DC: U.S. Government Printing Office, 1977:23-32.

7. Graham JE, Mitnitski AB, Mogilner AJ, et al. Dynamics of cognitive aging: distinguishing functional age and disease from chronologic age in a population. Am J Epidemiol 1999; 150:1045-1054.

8. Orimo H, Ito H, Susuki T, et al. Reviewing the definition of "elderly". Geriatr Gerontol Int 2006; 6:149-158.

9. de Zwart LL, Haenen HE, Versantvoort CH, et al. Role of biokinetics in risk assessment of drugs and chemicals in children. Regul Toxicol Pharmacol 2004; 39:282-309.

10. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004; 198:164-183.

11. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-1167.

12. Deren JS. Development of structure and function in the fetal and newborn stomach. Am J Clin Nutr 1971; 24:144-159.

13. Hyman PE, Feldman EJ, Ament ME, et al. Effect of enteral feeding on the maintenance of gastric acid secretory function. Gastroenterology 1983; 84:341-345.

14. Assael BM. Pharmacokinetics and drug distribution during postnatal development. Pharmacol Ther 1982; 18:159-197.

15. Gupta M, Brans YW. Gastric retention in neonates. Pediatrics 1978; 62:26-29.

16. Hendeles L, Iafrate RP, Weinberger M. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinet 1984; 9:95-135.

17. Jusko WJ, Levy G, Yaffe SJ. Effect of age on intestinal absorption of riboflavin in humans. J Pharm Sei 1970; 59:487^190.

18. Linday L, Dobkin JF, Wang TC, et al. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987; 79:544-548.

19. Heimann G. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol 1980; 18:43-50.

20. Pedersen-Bjergaard L, Petersen KE. Oral absorption of pivampicillin and ampicillin in young children: cross-over study using equimolar doses of a suspension. Clin Pharmacokinet 1977; 2: 451-456.

21. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32:481^195.

22. Murry DJ, Riva L, Poplack D. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer 1998; 78(S11):48-51.

23. Gilman JT, Duchowny MS, Resnick TJ, et al. Carbamazepine malabsorption: a case report. Pediatrics 1988; 82:518-519.

24. Friss-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961; 28:169-181.

25. Heimler R, Doumas BT, Jendrzejczak BM, et al. Relationship between nutrition, weight change, and fluid compartments in preterm infants during the first week of life. J Pediatr 1993; 122(1): 110-114.

26. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990; 18:20-36.

27. Milsap RL, Jusko WJ. Pharmacokinetics in the infant. Environ Health Perspect 1994; 102 (suppl 11): 107-110.

28. Gauntlett IS, Fisher DM, Hertzka RE, et al. Pharmacokinetics of fentanyl in neonatal humans and lambs: effects of age. Anesthesiology 1988; 69:683-687.

29. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 1997; 44:55-77.

30. Aranda JV, MacLeod SM, Renton KW, et al. Hepatic microsomal drug oxidation and electron transport in newborn infants. J Pediatr 1974; 85:534-542.

31. Rosen JP, Danish M, Ragni MC, et al. Theophylline pharmacokinetics in the young infant. Pediatrics 1979; 64:248-251.

32. Carrier O, Pons G, Rey E, et al. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther 1988; 44:145-151.

33. Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976; 19:284-294.

34. Glazer JP, Danish MA, Plotkin SA, et al. Disposition of chloramphenicol in low birth weight infants. Pediatrics 1980; 66:573-578.

35. Thompson JA, Bloedow DC, Leffert FH. Pharmacokinetics of intravenous chlorpheniramine in children. J Pharm Sei 1981; 70:1284-1286.

36. Fisher DG, Schwartz PH, Davis AL. Pharmacokinetics of exogenous epinephrine in critically ill children. Crit Care Med 1993; 21:111-117.

37. Matsuda I, Higashi A, Inotsume N. Physiologic and metabolic aspects of anticonvulsants. Pediatr Clin North Am 1989; 36:1099-1111.

38. Guignard JP, Torrado A, Da CO, et al. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975; 87:268-272.

39. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104:849-854.

40. McCance RA. Renal function in early life. Physiol Rev 1948; 28:331-348.

41. Stephenson T. How children's responses to drugs differ from adults. Br J Clin Pharmacol 2005; 59:670-673.

42. American Academy of Pediatrics: committee on drugs. "Inactive" ingredients in pharmaceutical products: update (Subject Review). Pediatrics 1997; 99:268-278.

43. Ernest TB, Elder DP, Martini LG, et al. Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 2007; 59:1043-1055.

44. Golightly LK, Smolinske SS, Bennett ML, et al. Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I). Med Toxicol Adverse Drug Exp 1988; 3:128-165.

45. Golightly LK, Smolinske SS, Bennett ML, et al. Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II). Med Toxicol Adverse Drug Exp 1988; 3:209-240.

46. Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children: role of excipients. Paediatr Drugs 2002; 4:371-379.

47. Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics 1997; 99:268-278.

48. Menon PA, Thach BT, Smith CH, et al. Benzyl alcohol toxicity in a neonatal intensive care unit. Incidence, symptomatology, and mortality. Am J Perinatol 1984; 1:288-292.

49. Committee on Fetus and Newborn, Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics 1983; 72:356-358.

50. Arulanantham K, Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr 1978; 93:515-516.

51. Anonymous. Yellow No 5. (tartrazine) labeling on drugs to be required. FDA Drug Bull 1979; 9(3): 18.

52. Pohl R, Balon R, Berchou R, et al. Allergy to tartrazine in antidepressants. Am J Psychiatry 1987; 144:237-238.

53. Weber RW, Hoffman M, Raine DA Jr., et al. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979; 64:32-37.

54. Buswell RS, Lefkowitz MS. Oral bronchodilators containing tartrazine. JAMA 1976; 235:1111.

55. McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 2007; 370:1560-1567.

56. Hill EM, Flaitz CM, Frost GR. Sweetener content of common pediatric oral liquid medications. Am J Hosp Pharm 1988; 45:135-142.

57. Strickley RG, Iwata Q, Wu S, et al. Pediatric drugs—a review of commercially available oral formulations. J Pharm Sci 2008; 97:1731-1774.

58. Shaw L, Glenwright HD. The role of medications in dental caries formation: need for sugar-free medication for children. Pediatrician 1989; 16:153-155.

59. Feigal RJ, Jensen ME, Mensing CA. Dental caries potential of liquid medications. Pediatrics 1981; 68(3):416-419.

60. Lokken P, Birkeland JM, Sannes E. pH changes in dental plaque caused by sweetened, iron-containing liquid medicine. Scand J Dent Res 1975; 83(5):279-283.

61. Mitchell H. Sweeteners and Sugar alternatives in food technology. London: Blackwell Publishing, 2007.

62. Lutomski DM, Gora ML, Wright SM, et al. Sorbitol content of selected oral liquids. Ann Pharmacother 1993; 27:269-274.

63. Arnold DL, Moodie CA, Grice HC, et al. Long-term toxicity of ortho-touenesulfonamide and sodium saccharin in the rat. Toxicol Appl Pharmacol 1980; 52:113-152.

64. Koysooko R, Levy G. Effect of ethanol on intestinal absorption of theophylline. J Pharm Sci 1974; 63:829-834.

65. Panel recommends limits on alcohol content of nonprescription products. FDA Over-The-Counter Drugs Advisory Committee. Am J Hosp Pharm 1993; 50:400.

66. Rappaport PL. Extemporaneous dosage preparations for pediatrics. Can J Hosp Pharm 1983; 36: 66-70, 74.

67. Standing JF, Khaki ZF, Wong IC. Poor formulation information in published pediatric drug trials. Pediatrics 2005; 116:e559-e562.

68. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005; 59:674-676.

69. Krause J, Breiktreutz J. Improving drug delivery in paediatric medicines. Pharm Med 2008; 22: 41-50.

70. Griessmann K, Breitkreutz J, Schubert-Zsilavecz M, et al. Dosing accuracy of measuring devices provided with antibiotic oral suspensions. Paediatr Perinat Drug Ther 2007; 10:61-70.

71. Brown D, Ford JL, Nunn AJ, et al. An assessment of dose-uniformity of samples delivered from paediatric oral droppers. J Clin Pharm Ther 2004; 29:521-529.

72. Standing JF, Tuleu C. Paediatric formulations—getting to the heart of the problem. Int J Pharm 2005; 300:56-66.

73. Blumer JL. Fundamental basis for rational therapeutics in acute otitis media. Pediatr Infect Dis J 1999; 18:1130-1140.

74. Teng J, Song CK, Williams RL, et al. Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc 2002; 42:195-199.

75. Tuleu C, Grange J, Seurin S. The need of paediatric formulation: administration of nifedipine in children, a proof of concept. J Drug Del Sci Tech 2005; 15:319-324.

76. Abdel-Rahman SM, Blowey DL, Kauffmann RE, et al. Comparative bioavailability of loracarbef chewable tablet vs. oral suspension in children. Pediatr Infect Dis J 1998; 17: 1171-1173.

77. Cornaggia C, Gianetti S, Battino D, et al. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children. Epilepsia 1993; 34:158-160.

78. Cloyd JC, Kriel RL, Jones-Saete CM, et al. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr 1992; 120:634-638.

79. Nowak MM, Brundhofer B, Gibaldi M. Rectal absorption from aspirin suppositories in children and adults. Pediatrics 1974; 54:23-26.

80. Ghadially R, Shear N. Topical therapy and percutaneous absorption. In: Yaffe SJ, Aranda JV, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. 2nd ed. Philadelphia: WB Saunders, 1992:72-77.

81. Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev 1998; 19:423^128.

82. Paisley JW, Smith AL, Smith DH. Gentamicin in newborn infants. Comparison of intramuscular and intravenous administration. Am J Dis Child 1973; 126:473-477.

83. Shann F, Linnemann V, Mackenzie A, et al. Absorption of chloramphenicol sodium succinate after intramuscular administration in children. N Engl J Med 1985; 313:410-414.

84. Bradley JS, Compogiannis LS, Murray WE, et al. Pharmacokinetics and safety of intramuscular injection of concentrated certriaxone in children. Clin Pharm 1992; 11:961-964.

85. Suarez EC, Grippi JR. Comparative bioavailability and safety of two intramuscular ceftriaxone formulations. Ann Pharmacother 1996; 30:1223-1226.

86. Seay RE. Comment: bioavailability and safety of two ceftriaxone formulations - exposure to lidocaine questioned. Ann Pharmacother 1997; 31:501-502.

87. Mclvor A, Paluzzi M, Meguid MM. Intramuscular injection abscess—past lessons relearned. N Engl J Med 1991; 324:1897-1898.

88. Hard R. Pharmacists work on pediatric dosage problems. Hospitals 1992; 66:46-48.

89. Koren G, Barzilay Z, Greenwald M. Tenfold errors in administration of drug doses: a neglected Iatrogenic disease in pediatrics. Pediatrics 1986; 77:848-849.

90. Goldman RD. Intranasal drug delivery for children with acute illness. Curr Drug Ther 2006; 1: 127-130.

91. Johnston C. Endotracheal drug delivery. Pediatr Emerg Care 1992; 8:94-97.

92. Hickey AJ. Factors influencing aerosol desposition in inertial impactors and their effect on particle size characterization. Pharm Technol 1990; 14:118-130.

93. Abrolat ML, Nguyen LP, Saca LF. Hold it! Correct use of inhalers in children with asthma. West J Med 2001; 175:303-304.

94. Saggers BA, Lawson D. Some observations on the penetration of antibiotics through mucus in vitro. J Clin Pathol 1966; 19:313-317.

95. Saggers BA, Lawson D. In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Child 1968; 43:404^109.

96. Gibaldi M. Understanding and treating some genetic diseases. Ann Pharmacother 1992; 26: 1589-1594.

97. Jew LL, Hart LL. Inhaled aminoglycosides in cystic fibrosis. DICP 1990; 24:711-712.

98. Ross B, Ramsey L, Shepherd J. Delivery of aerosol therapy in the management of pulmonary disorders. Hosp Pharm Rep 2000; 14:3.

99. Matsui D. Assessing the palatability of medication in children. Paediatr Perinat Drug Ther 2007; 8:55-60.

100. Mennella JA, Pepino MY, Reed DR. Genetic and environmental determinants of bitter perception and sweet preferences. Pediatrics 2005; 115:e216-e222.

101. James CE, Laing DG, Oram N. A comparison of the ability of 8-9-year-old children and adults to detect taste stimuli. Physiol Behav 1997; 62:193-197.

102. James CE, Laing DG, Oram N, et al. Perception of sweetness in simple and complex taste stimuli by adults and children. Chem Senses 1999; 24:281-287.

103. Mantick N, Jantz C. Children's OTC pharmaceuticals: sensory directed flavor formulation. Profile Attribute Analysis. Cambridge, MA: Arthur D Little, 1991.

104. Kumar A, Weatherly MR, Beaman DC. Sweeteners, flavorings, and dyes in antibiotic preparations. Pediatrics 1991; 87:352-360.

105. Ruff ME, Schotik DA, Bass JW, et al. Antimicrobial drug suspensions: a blind comparison of taste of fourteen common pediatric drugs. Pediatr Infect Dis J 1991; 10:30-33.

106. Roberts J, Turner N. Pharmacodynamic basis for altered drug action in the elderly. Clin Geriatr Med 1988; 4:127-149.

107. Vestal RE. Drug use in the elderly: a review of problems and special considerations. Drugs 1978; 16:358-382.

108. Rocci ML Jr., Vlasses PH, Abrams WB. Geriatric clinical pharmacology. Cardiol Clin 1986; 4:213-225.

109. Cromarty JA. Medicines for the elderly. Pharm J 1985; 235:511.

110. Pucino F, Beck CL, Seifert RL, et al. Pharmacogeriatrics. Pharmacotherapy 1985; 5:314-326.

111. Miura T, Kojima R, Sugiura Y, et al. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother 2000; 34:427^132.

112. Crooks J, O'Malley K, Stevenson IH. Pharmacokinetics in the elderly. Clin Pharmacokinet 1976; 1:280-296.

113. Kean WF, Buchanan WW. Pharmacokinetics of NSAID with special reference to the elderly. Singapore Med J 1987; 28:383-389.

114. A report of Royal College of Physicians. Medications for the elderly. J Royal Coll of Physicians of Lond 1984; 18:1-7.

115. Mayersohn M. Drug disposition in the elderly. In: Penta FB, ed. Pharmacy Practice for the Geriatric Patient. Alexandria, VA: American Association of Colleges of Pharmacy, 1986:9.5-9.11.

116. Shepherd AMM. Physiological changes with aging^-elevance to drug study design. In: Cutler NR, Narang PK, eds. Drug Studies in the Elderly: Methodological Concerns. New York: Plenum Publishing, 1986:50-54.

117. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67: 512-520.

118. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 2000; 38:271-290.

119. Bachmann KA, Belloto RJ Jr. Differential kinetics of phenytoin in elderly patients. Drugs Aging 1999; 15:235-250.

120. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57.

121. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68:28-34.

122. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16:165-177.

123. Cohen JS. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients. Geriatrics 2000; 55:54-60, 63.

124. Castleden CM, Volans CN, Raymond K. The effect of ageing on drug absorption from the gut. Age Ageing 1977; 6:138-143.

125. Gerbino PP, Wordell CJ. Gastrointestinal disorder. In: Penta FB, ed. Pharmacy Practice for the Geriatric Patient. Alexandria, VA: American Association of Colleges of Pharmacy, 1986:20.1-20.24.

126. Sheely TW. The gastrointestinal system and the elderly. In: Gambert SR, ed. Contemporary Geriatric Medicine. 2nd ed. New York: Plenum Publishing, 1986.

127. Geokas MC, Haverback BJ. The aging gastrointestinal tract. Am J Surg 1969; 117:881-892.

128. Holt PR. Gastrointestinal drugs in the elderly. Am J Gastroenterol 1986; 81:403-411.

129. Anuras S, Loening-Baucke V. Gastrointestinal motility in the elderly. J Am Geriatr Soc 1984; 32: 386-390.

130. Moore JG, Tweedy C, Christian PE, et al. Effect of age on gastric emptying of liquid-solid meals in man. Dig Dis Sei 1983; 28:340-344.

131. Evans MA, Triggs EJ, Cheung M, et al. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981; 29:201-205.

132. Evans MA, Broe GA, Triggs EJ, et al. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 1981; 31:1288-1294.

133. Mojaverian P, Vlasses PH, Kellner PE, et al. Effects of gender, posture, and age on gastric residence time of an indigestible solid: pharmaceutical considerations. Pharm Res 1988; 5: 639-644.

134. Gryback P, Hermansson G, Lyrenas E, et al. Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. Eur J Nucl Med 2000; 27:647-555.

135. Baum BJ, Bodner L. Aging and oral motor function: evidence for altered performance among older persons. J Dent Res 1983; 62:2-6.

136. Ben-Aryeh H, Miron D, Berdicevsky I, et al. Xerostomia in the elderly: prevalence, diagnosis, complications and treatment. Gerodontology 1985; 4:77-82.

137. Collins JG. Prevalence of selected chronic conditions: United States, 1990-1992. Vital National Health 1997; 10(194): 1-89.

138. Exton-Smith AN, Weksler ME. Practical Geriatric Medicine. New York: Churchill Livingstone, 1985.

139. Ferguson BD. The Aging Mouth (Frontiers of Oral Physiology). 2nd ed. New York: S. Karger 1988.

140. Kamen S, Kamen LB. Contemporary Geriatric Medicine. In: Gambert SR,ed. New York: Plenum Publishing, 1986.

141. National Center for Health Statistics (NCHS). Health, United States, 1999, with Health and Aging Chartbook. Hyattsville, MD: DHSS eds. (US department of Health and Human Services), 1999. Available at: http://www.cdc.gov/nchs/data/hus/hus99ncb.pdf.

142. Christophers E, Kligman AM. Percutaneous adsorption in aged skin. In: Montagna W, ed. Advances in Biology of the Skin. New York: Permagon Press, 1964:163-175.

143. Behl CG, Bellantone NH, Flynn GL. Influence of age on percutaneous absorption of drug substance. In: Kyodonieus AF, Berner B, eds. Transdermal Delivery of Drugs. Boca Raton, FL: CRC Press, 1998:109-132.

144. Kligman AM. Perspectives and problems in cutaneous gerontology. J Invest Dermatol 1979; 73: 39-46.

145. Daly CH, Ödland GF. Age-related changes in the mechanical properties of human skin. J Invest Dermatol 1979; 73:83-87.

146. Adams PF, Benson V. Current estimates from the National Health Interview Survey. Vital Health Stat 1990; 10(181): 1-212.

147. Branch LG, Katz S, Kniepmann K, et al. A prospective study of functional status among community elders. Am J Public Health 1984; 74:266-268.

148. Cornoni-Huntley J, Brock DB, Ostfeld AM, et al. Established Populations for Epidemiologic Studies for the Elderly. Washington, DC: U.S. Government Printing Office, 1986.

149. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970; 10:20-30.

150. National Center for Health Statistics. Health, United States, 2000, Adolescent Health Chartbook. Hyattsville, MD: DHSS eds., 2000. Available at: http://www.cdc.gov/nchs/data/ hus/hus00.pdf.

151. Cerella J. Age-related decline in extrafoveal letter perception. J Gerontol 1985; 40:727-736.

152. Kosnik W, Winslow L, Kline D, et al. Visual changes in daily life throughout adulthood. J Gerontol 1988; 43:63-70.

153. Maloney CC. Identifying and treating the client with sensory loss. Phys Occup Ther Geriatr 1987; 5:31.

154. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007; 4:165-174.

155. Kircher V. Ergonomische Probleme individuell lösen. Pharm Ztg 2005; 150:4570-4577.

156. Kircher V. Wie sich ergonomische und audiologische Probleme lösen lassen. Pharm Ztg 2007; 152: 2404-2413.

157. Heeneman H, Brown DH. Senescent changes in and about the oral cavity and pharynx. J Otolaryngol 1986; 15:214-216.

158. Lamy PP. Over-the-counter medication: the drug interactions we overlook. J Am Geriatr Soc 1982; 30(11 suppl):S69-S75.

159. Lamy PP. Appropriate and inappropriate drug use. In: Penta FB, ed. Pharmacy Practice for the Geriatric Patient. Alexandria, VA: American Association of Colleges of Pharmacy, 1985:13.1-13.27.

160. Fuselier CC. General principles of drug prescribing. In: Penta FB, ed. Pharmacy Practice for the Geriatric Patient. Alexandria, VA: American Association of Colleges of Pharmacy, 1985:8.1-8.28.

161. Channer KS, Viijee JP. The effect of formulation on oesophageal transit. J Pharm Pharmacol 1985; 37:126-129.

162. Hey H, Jorgensen F, Sorensen K, et al. Oesophageal transit of six commonly used tablets and capsules. Br Med J (Clin Res Ed) 1982; 285:1717-1719.

163. Kottke MK, Stetsko G, Rosenbaum SR, et al. Problems encountered by the elderly in the use of conventional dosage forms. J Geriatr Drug Ther 1990; 5:77-91.

164. Marvola M, Rajaniemi M, Marttila E, et al. Effect of dosage form and formulation factors on the adherence of drugs to the esophagus. J Pharm Sei 1983; 72:1034—1036.

165. Semla T, Breizer J, Higbee M. Geriatric Dosage Handbook. Washington, DC: American Pharmaceutical Association, 2000.

166. Hollenbeck RG, Lamy PP. Dosage form considerations in clinical trials involving elderly patients. In: Cutler NR, Narang PK, eds. Drug Studies in the Elderly. Methodological Concerns. New York: Plenum Publishing, 1986:335-353.

167. Wallace RB. Drug utilization in the rural elderly: Perspectives from a population study. In: Moore SR, Teal RW, eds. Geriatric Drug Use-Clinical and Social Perspectives. New York: Permagon Press, 1985:78-85.

168. Finchman JB. Over-the-counter drug use and misuse by the ambulatory elderly: a review of the literature. J Geriatr Drug Ther 1986; 1:3.

169. Hallworth RB, Goldberg LA. Geriatric patients' understanding of labelling of medicines. Br J Pharm Pract 1984; 6:6-14.

170. Lamy PP. The future is not what it used to be. Mol Pharm 1987; 63:10.

171. Richardson JL. Perspectives on compliance with drug regimens among the elderly. J Compliance Health Care 1986; 1:33.

172. Simonson W. Compliance to drug therapy. Medications and the Elderly. A Guide to Promoting Proper Use. Baltimore: Aspen Publishers, 1984:70-79.

173. Sumner BD. Compliance with drug therapy. Handbook of Geriatric Drug Therapy for Health Care Professionals. Philadelphia: Lea & Febiger, 1983:43-52.

174. Wade B, Bowling A. Appropriate use of drugs by elderly people. J Adv Nurs 1986; 11:47-55.

175. Williamson JR, Smith RG, Burley LE. Primary Care of the Elderly. A Practical Approach. London: IOP Publishing, 1987.

176. Wong BS, Norman DC. Evaluation of a novel medication aid, the calendar blister-pak, and its effect on drug compliance in a geriatric outpatient clinic. J Am Geriatr Soc 1987; 35:21-26.

177. Keram S, Williams ME. Quantifying the ease or difficulty older persons experience in opening medication containers. J Am Geriatr Soc 1988; 36:198-201.

178. Davidson JR. Presentation and packaging of drugs for the elderly. J Hosp Pharm 1973; 31:180.

179. United States Pharmacopeial Convention. Fourth Supplement of the United States Pharmacopeia National Formulary. Rockville, MD, 1988.

180. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, eds. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia, PA: Lea & Febiger, 1986.

181. Tsumara J, inventor; Process for the preparation of water-soluble tablets. US patent 3,692, 896. 1972.

182. Crivellaro G, Oldani F, inventors; Soluble tablet. US patent 3,819,824 1974.

183. Daunora LG, inventor; Water soluble tablet. US patent 4,347,235 1982.

184. Martini T. Tablet dispersion as alternative to mixtures. NZ Pharm 1987; 7:34.

185. Norris E, Guttadauria M. Piroxicam: new dosage forms. Eur J Rheumatol Inflamm 1987; 8: 94-104.

186. Heinemann H, Rothe W. Preparation of porous tablets. US patent 3,885,026 1975.

187. Corveleyn S, Remon JP. Stability of freeze-dried tablets at different relative humidities. Drug Dev Ind Pharm 1999; 25:1005-1013.

188. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50:375-382.

189. Hanawa T, Watanabe A, Tsuchiya T, et al. New oral dosage form for elderly patients: preparation and characterization of silk fibroin gel. Chem Pharm Bull (Tokyo) 1995; 43:284—288.

190. Hanawa T, Maeda R, Muramatsu E, et al. New oral dosage form for elderly patients. III. Stability of trichlormethiazide in silk fibroin gel and various sugar solutions. Drug Dev Ind Pharm 2000; 26:1091-1097.

191. Watanabe A, Hanawa T, Sugihara M, et al. Release profiles of phenytoin from new oral dosage form for the elderly. Chem Pharm Bull (Tokyo) 1994; 42:1642-1645.

192. Tovey GD. The development of the Tiltab tablets. Pharm J 1987; 239:363.

193. Murphy C. Aging and chemosensory perception. Front Oral Physiol 1987; 6:135.

194. Spitzer ME. Taste acuity in institutionalized and noninstitutionalized elderly men. J Gerontol 1988; 43:71-74.

195. Cooper BA. A model for implementing color contrast in the environment of the elderly. Am J Occup Ther 1985; 39:253-258.

196. Zuccollo G, Liddell H. The elderly and the medication label: doing it better. Age Ageing 1985; 14: 371-376.

197. Sumner BD. General considerations. Handbook of Geriatric Drug Therapy for Health Care Professionals. Philadelphia: Lea & Febiger, 1983:1-9.

Was this article helpful?

0 0

Post a comment